Evidence brief
Abaloparatide
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
An FDA-approved product exists for defined osteoporosis populations.
An approved osteoporosis medicine with fracture evidence in defined groups and product-specific safety limits.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Not assessed
No current sports-rule review is available.
Reviewed July 23, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Tymlos · BA058 · PTHrP analogue
Part of Bone peptide medicines
Words used here
- outcome
- what the study measured
- analog
- a changed version made to act like another substance
- placebo
- an inactive treatment used for comparison
- open-label
- a study in which people and researchers know which treatment was given
- randomized
- assigned to study groups by chance
- indication
- the approved or studied use and patient group
- benefit-risk
- a comparison of possible benefits with possible harms for a defined use and group
- peptide
- a short chain of amino acids
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
The ACTIVE phase 3 trial supports fracture-risk reduction in postmenopausal women with osteoporosis.
Approved labeling characterizes PTH1-receptor activity, exposure, and bone-turnover effects.
Known risks and monitoring are described in the current product label.
High for authentic Tymlos used within the approved label.
02 · Identity
What it is
Abaloparatide is a man-made version of a parathyroid hormone-related peptide. It acts at the PTH1 receptor and is used as a medicine to help build bone.
Scientific group: Parathyroid hormone-related peptide analogue. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Tymlos
2025 label- Formulation
- Injection pen
- Route
- Subcutaneous
- Indication scope
- Osteoporosis uses in the high-fracture-risk populations defined in the product label.
- Tymlos
- Osteoporosis treatment or bone-density increase in labeled high-risk populations
04 · Research results
What the research shows
The ACTIVE study compared abaloparatide with placebo or open-label teriparatide in postmenopausal women with osteoporosis. Abaloparatide reduced new spine and non-spine fractures versus placebo over 18 months.
The result does not establish that it is better than every osteoporosis medicine, improves healthy people, or heals every new injury better.
Exact product
The study result belongs to the named prescription product, not every similar product or use. Tymlos is a product-specific prescription medicine. Trial findings do not validate unapproved PTHrP analogues or general performance use.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Abaloparatide reduced fractures in a randomized phase 3 trial.”
ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Postmenopausal women with osteoporosis at fracture risk over 18 months. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Abaloparatide is proven to improve bone outcomes in every population.”
Approved indications and trial populations define the evidence boundary.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Populations outside the current label and pivotal trial. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“An anabolic bone effect means abaloparatide is a safe performance enhancer.”
A prescription osteoporosis benefit-risk assessment does not establish safe enhancement in healthy people.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Healthy or athletic performance use. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Abaloparatide
An FDA-approved product exists for defined osteoporosis populations. Approved products identified: Tymlos.
Not assessed. This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body. This status is not personal clearance to compete.
The ACTIVE study compared abaloparatide with placebo or open-label teriparatide in postmenopausal women with osteoporosis. Abaloparatide reduced new spine and non-spine fractures versus placebo over 18 months.
The result does not establish that it is better than every osteoporosis medicine, improves healthy people, or heals every new injury better.
07 · Safety
Safety limits for this record
This prescription osteoporosis medicine has product-specific warnings and limits on use. No dose, injection, or performance guidance is provided.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
No current sports-rule review is available.
Reviewed .Check current rules for tested sport ↗08 · Sources
Read the sources
09 · Review history
Review history
Initial brief based on the 2025 Tymlos label and ACTIVE phase 3 trial.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.